Document is current
Any future updates will be listed below
-
Authors
Kidoguchi, Genki https://orcid.org/0009-0001-0558-8814
Yoshida, Yusuke
Watanabe, Hirofumi
Sugimoto, Tomohiro
Mokuda, Sho
Kida, Takashi
Yajima, Nobuyuki
Omura, Satoshi
Nakagomi, Daiki
Abe, Yoshiyuki
Kadoya, Masatoshi
Takizawa, Naoho
Nomura, Atsushi
Kukida, Yuji
Kondo, Naoya
Yamano, Yasuhiko
Yanagida, Takuya
Endo, Koji
Matsui, Kiyoshi
Takeuchi, Tohru
Ichinose, Kunihiro
Kato, Masaru
Yanai, Ryo
Matsuo, Yusuke
Shimojima, Yasuhiro
Nishioka, Ryo
Okazaki, Ryota
Takata, Tomoaki
Ito, Takafumi
Moriyama, Mayuko
Takatani, Ayuko
Miyawaki, Yoshia
Ito-Ihara, Toshiko
Kawaguchi, Takashi
Kawahito, Yutaka
Hirata, Shintaro
,
-
Funding
Funding for this research was provided by:
Hiroshima University
- License Information
-
More Information
Article History
Received: 5 March 2024
Revised: 30 July 2024
Accepted: 1 August 2024
First Online: 12 August 2024
Declarations
:
: Ethics approval was granted by the Ethics Committee for Epidemiological Research of Hiroshima University (approval number: E-2021–2465). This study was conducted in accordance with the ethical standards of the Declaration of Helsinki, and the requirement for written consent was waived because of the retrospective nature of the study. Approval dates and names of the ethics committees at participating centres are provided in Supplemental Table .An abstract of the data from this study, limited to older individuals, has been published in the “2023 EULAR Congress Abstract Book”. Kidoguchi G, Yoshida Y, Watanabe H et al. (2023) AB0786 induction therapy with rituximab enables sustained remission in elderly patients with relapsed ANCA-associated vasculitis: a retrospective analysis from J-CANVAS, a Japanese multicentre-cohort. Ann Rheum Dis 82:1603–1604. .
: We disclose the following conflicts of interest with pharmaceutical companies promoting RTX or RTX biosimilars as outlined below. Yusuke Yoshida: speaker fees — Chugai. Takashi Kida: speaker fees — Chugai. Daiki Nakagomi: scholarship donations, speaker fees — Chugai. Naoho Takizawa: speaker fees — Chugai, Kyowa Hakko Kirin, Pfizer. Yuji Kukida: speaker fees — Chugai, Pfizer. Kiyoshi Matsui: research grants — Chugai. Masaru Kato: speaker fees — Chugai, Pfizer. Tomoaki Takata: speaker fees — Chugai; scholarship donations, speaker fees — Kyowa Hakko Kirin. Takafumi Ito: speaker fees — Chugai, Kyowa Hakko Kirin. Takashi Kawaguchi: speaker fees, consultancy — Chugai; speaker fees — Kyowa Hakko Kirin. Yutaka Kawahito: speaker fees, research grants — Chugai; speaker fees — Pfizer. Shintaro Hirata: speaker fees, consultancy fees, research grants — Chugai, Pfizer and additional relationships, including speaker fees, consultancy fees, research grants and honoraria with AbbVie; Asahi — Kasei Pharma; Astellas; AstraZeneca; Ayumi; Bristol Myers Squibb; Boehringer Ingelheim; Daiichi — Sankyo; Eisai; Gilead Sciences; GlaxoSmithKline; Eli Lilly; Janssen; Nippon Shinyaku; Novartis; Otsuka; Taisho; Tanabe — Mitsubishi; and UCB.
